-
Spinraza Wins 'Best Case Approval'; Leerink Raises Targets On Biogen, Ionis
Tuesday, December 27, 2016 - 11:56am | 337Read More...The FDA has approved Spinraza for the treatment of all types of spinal muscular atrophy. The approval comes six months earlier than expected and with a label that is “as broad as even the most optimistic patient or investor could have hoped for,” Leerink’s Geoffrey C. Porges said...
-
Leerink: Medivation Buyout 'Inevitable,' AstraZeneca And AbbVie Most Likely Buyers
Monday, April 25, 2016 - 10:51am | 324Read More...Leerink’s Geoffrey C. Porges believes that acquirer interest in Medivation Inc (NASDAQ: MDVN) and the appreciation in the stock valuation as “evidence of investors’ views that more value lies in the sale of the company vs. its independence.” Porges maintained a Market...
-
Data Shows Gilead's HCV Franchise Is Surviving New Competition
Monday, March 28, 2016 - 10:47am | 304Read More...Leerink’s Geoffrey C. Porges maintained an Outperform rating on Gilead Sciences, Inc. (NASDAQ: GILD), with a price target of $127. Porges mentioned that “current analysis of IMS script data and review of the largest payer plan formularies reveal that Gilead’s HCV DAAs are...
-
Leerink Raises Gilead Target To $130 On New HIV Outlook
Tuesday, March 8, 2016 - 10:52am | 249Read More...Leerink’s Geoffrey C. Porges maintained an Outperform rating for Gilead Sciences, Inc. (NASDAQ: GILD), while raising the price target from $125 to $130. The analyst said that the company’s new HIV franchise outlook reflected TAF adoption. Gilead Sciences dominates the market for two...
-
Analysts Diverge On Celgene's Deal With Juno Therapeutics
Tuesday, June 30, 2015 - 11:37am | 381Read More...Whether Celgene Corporation (NASDAQ: CELG) went too far in its $1 billion development deal with Juno Therapeutics Inc (NASDAQ: JUNO) is a matter for speculation. Celgene unveiled an agreement late Monday in which it will pay Juno $150 million and acquire about $850 million in Juno shares in...
